v3.25.1

Consolidated companies as of December 31, 2024 | 12 Months Ended
--- | ---
Dec. 31, 2024
Consolidated companies as of December 31, 2023 |
Consolidated companies as of December 31, 2023 | 34. Consolidated companies as of December 31, 2024 ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Year ended December 31,
​ | ​ | ​ | ​ | 2024 | ​ | 2023 | ​ | 2022
Name of the subsidiary |  | Country |  | % voting right Galapagos NV (directly or indirectly through subsidiaries) |  | Change in % voting right previous period (2024 vs 2023) |  | % voting right Galapagos NV (directly or indirectly through subsidiaries) |  | % voting right Galapagos NV (directly or indirectly through subsidiaries)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CONTINUING OPERATIONS | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
GLPG US Inc. (formerly AboundBio Inc.) | ​ | United States | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
CellPoint B.V. (till 11/30/2023) | ​ | The Netherlands | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos B.V. (merged with CellPoint B.V.) | ​ | The Netherlands | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos GmbH | ​ | Switzerland | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
GLPG US Holding Inc. (formerly Galapagos, Inc.) | ​ | United States | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos NV | ​ | Belgium | ​ | Parent company | ​ | ​ | ​ | Parent company | ​ | Parent company
Galapagos Real Estate Belgium BV (former Galapagos Real Estate 1 BV) | ​ | Belgium | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos Real Estate Netherlands B.V. | ​ | The Netherlands | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos U.K. Limited | ​ | United Kingdom | ​ | 100% | ​ | 100% | ​ | 0% | ​ | 0%
Galapagos SASU | ​ | France | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Xenometrix, Inc. in liquidation | ​ | United States | ​ | 100% | ​ | ​ | ​ | 100% | ​ | 100%
Galapagos Holding PTE. LTD. | ​ | Singapore | ​ | 100% | ​ | 100% | ​ | 0% | ​ | 0%
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
DISCONTINUED OPERATIONS | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Galapagos Biopharma Belgium BV | ​ | Belgium | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Netherlands B.V. | ​ | The Netherlands | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Spain S.L.U. | ​ | Spain | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Italy S.r.l. | ​ | Italy | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Germany GmbH | ​ | Germany | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Sweden AB | ​ | Sweden | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Norway AS | ​ | Norway | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Finland Oy | ​ | Finland | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Denmark ApS | ​ | Denmark | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Austria GmbH | ​ | Austria | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biopharma Ireland Ltd | ​ | Ireland | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
Galapagos Biotech Ltd (formerly Inpharmatica Ltd.) | ​ | United Kingdom | ​ | 0% | ​ | -100% | ​ | 100% | ​ | 100%
​ There are no significant restrictions on the group’s ability to access or use assets and settle liabilities of one of the group’s subsidiaries. ​ In December 2024, we signed a share purchase agreement regarding the shares of Galapagos Real Estate Belgium BV. We expect closing of this transaction to occur by March 31, 2025. ​ On January 7, 2025, we incorporated Galapagos (Shanghai) Bioscience Co., Ltd., in the People’s Republic of China, and on February 14, 2025 we incorporated XYZ SpinCo NV.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration